Luo Song, Huang Kaifang, Zhao Xiaoyu, Cong Yalong, Zhang John Z H, Duan Lili
School of Physics and Electronics, Shandong Normal University, Jinan, 250014, China.
Nanoscale. 2021 May 7;13(17):8313-8332. doi: 10.1039/d0nr07833f. Epub 2021 Apr 26.
Coronavirus disease 2019 (COVID-19), which is caused by a new coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading around the world. However, a universally effective treatment regimen has not been developed to date. The main protease (M), a key enzyme of SARS-CoV-2, plays a crucial role in the replication and transcription of this virus in cells and has become the ideal target for rational antiviral drug design. In this study, we performed molecular dynamics simulations three times for these complexes of M (monomeric and dimeric) and nine potential drugs that have a certain effect on the treatment of COVID-19 to explore their binding mechanism. In addition, a total of 12 methods for calculating binding free energy were employed to determine the optimal drug. Ritonavir, Arbidol, and Chloroquine consistently showed an outstanding binding ability to monomeric M under various methods. Ritonavir, Arbidol, and Saquinavir presented the best performance when binding to a dimer, which was independent of the protonated state of Hie41 (protonated at N) and Hid41 (protonated at N), and these findings suggest that Chloroquine may not effectively inhibit the activity of dimeric Min vivo. Furthermore, three common hot-spot residues of Met165, Hie41, and Gln189 of monomeric M systems dominated the binding of Ritonavir, Arbidol, and Chloroquine. In dimeric M, Gln189, Met165, and Met49 contributed significantly to binding with Ritonavir, Arbidol, and Saquinavir; therefore, Gln189 and Met165 might serve as the focus in the discovery and development of anti-COVID-19 drugs. In addition, the van der Waals interaction played a significant role in the binding process, and the benzene ring of the drugs showed an apparent inhibitory effect on the normal function of M. The binding cavity had great flexibility to accommodate these different drugs. The results would be notably helpful for enabling a detailed understanding of the binding mechanisms for these important drug-M interactions and provide valuable guidance for the design of potent inhibitors.
2019冠状病毒病(COVID-19)由一种名为严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的新型冠状病毒引起,正在全球范围内传播。然而,迄今为止尚未开发出一种普遍有效的治疗方案。主要蛋白酶(M)是SARS-CoV-2的关键酶,在该病毒在细胞内的复制和转录中起关键作用,已成为合理设计抗病毒药物的理想靶点。在本研究中,我们对M(单体和二聚体)与九种对COVID-19治疗有一定效果的潜在药物的复合物进行了三次分子动力学模拟,以探索它们的结合机制。此外,总共采用了12种计算结合自由能的方法来确定最佳药物。在各种方法下,利托那韦、阿比多尔和氯喹对单体M始终表现出出色的结合能力。利托那韦、阿比多尔和沙奎那韦在与二聚体结合时表现最佳,这与Hie41(N质子化)和Hid41(N质子化)的质子化状态无关,这些发现表明氯喹可能无法在体内有效抑制二聚体M的活性。此外,单体M系统中三个常见的热点残基Met165、Hie41和Gln189主导了利托那韦、阿比多尔和氯喹的结合。在二聚体M中,Gln189、Met165和Met49对与利托那韦、阿比多尔和沙奎那韦的结合有显著贡献;因此,Gln189和Met165可能成为抗COVID-19药物发现和开发的重点。此外,范德华相互作用在结合过程中起重要作用,药物的苯环对M的正常功能有明显抑制作用。结合腔具有很大的灵活性以容纳这些不同的药物。这些结果将有助于详细了解这些重要药物-M相互作用的结合机制,并为设计有效的抑制剂提供有价值的指导。